DISPOSITION OF CLOZAPINE AND DESMETHYLCLOZAPINE IN SCHIZOPHRENIC-PATIENTS

被引：34
|
作者：
LIN, SK
CHANG, WH
CHUNG, MC
LAM, YWF
JANN, MW
机构：
[1] TAIPEI CITY PSYCHIAT CTR,BIOL PSYCHIAT LAB,TAIPEI 10510,TAIWAN
[2] UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL,DIV CLIN PHARM,SAN ANTONIO,TX 78284
[3] UNIV TEXAS,COLL PHARM,AUSTIN,TX 78712
[4] MERCER UNIV,DEPT PHARM PRACTICE,ATLANTA,GA
[5] MERCER UNIV,DEPT PHARMACEUT SCI,ATLANTA,GA
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 1994年 / 34卷 / 04期
关键词：
D O I：
10.1002/j.1552-4604.1994.tb02000.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The disposition of the atypical clozapine and its desmethyl metabolite were evaluated in fourteen male chronic patients. A single 100 mg dose of clozapine was administered and blood sampling performed over the following 72 hours. The mean (SD) oral clearance and half-life of clozapine were 55.4 (29.7) L/hr and 13.7 (9.9) hours, respectively. The mean (SD) AUC for clozapine and desmethylclozapine was 2389.9 (1406) and 751.1 (622.9) ng.hr/mL, respectively. The elimination of the metabolite is rate limited by its formation from cloza-pine. A wide interpatient variability in clozapine and desmethylclozapine pharmacokinetics was observed.
引用
收藏
页码：318 / 324
页数：7
相关论文
共 50 条
  • [1] DISPOSITION OF CLOZAPINE AND DESMETHYLCLOZAPINE IN SCHIZOPHRENIC-PATIENTS
    LIN, SK
    CHANG, WH
    LAM, FYW
    JANN, MW
    CHIEN, CP
    NEUROPSYCHOPHARMACOLOGY, 1993, 9 (02) : S118 - S118
  • [2] DISPOSITION OF GLYCOSAMINOGLYCANS EXCRETED IN URINE OF SCHIZOPHRENIC-PATIENTS
    VARMA, R
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1978, 176 (SEP): : 6 - 6
  • [3] THE REHABILITATION AND DISPOSITION OF CHRONICALLY HOSPITALIZED SCHIZOPHRENIC-PATIENTS
    ELLSWORTH, RB
    MEAD, BT
    CLAYTON, WH
    MENTAL HYGIENE, 1958, 42 (03) : 343 - 348
  • [4] CLOZAPINE CONCENTRATIONS AND CLINICAL-RESPONSE IN SCHIZOPHRENIC-PATIENTS
    OWEN, JA
    DELVA, NJ
    LAWSON, JS
    AMERICAN JOURNAL OF PSYCHIATRY, 1992, 149 (08): : 1120 - 1121
  • [5] SEROTONIN FUNCTION AND TREATMENT RESPONSE TO CLOZAPINE IN SCHIZOPHRENIC-PATIENTS
    KAHN, RS
    DAVIDSON, M
    SIEVER, L
    GABRIEL, S
    APTER, S
    DAVIS, KL
    AMERICAN JOURNAL OF PSYCHIATRY, 1993, 150 (09): : 1337 - 1342
  • [6] EFFICACY AND TOLERABILITY OF CLOZAPINE IN THE TREATMENT OF 425 SCHIZOPHRENIC-PATIENTS
    NABER, D
    HIPPIUS, H
    SCHIZOPHRENIA RESEARCH, 1991, 4 (03) : 322 - 323
  • [7] CLOZAPINE IN THE TREATMENT OF SCHIZOPHRENIC-PATIENTS - AN INTERNATIONAL MULTICENTER TRIAL
    PANTELEEVA, GP
    KOVSKAYA, MYT
    BELYAEV, BS
    MINSKER, EI
    VYNAR, O
    CESKOVA, E
    SVETSKA, J
    LIBIGER, J
    KORINKOVA, V
    NOVOTNY, V
    FILIP, V
    PAVLOVSKY, P
    ZOLTY, G
    GASNER, P
    STANISLAV, D
    WELBEL, M
    KETNER, M
    POPOV, G
    GRUNES, E
    CLINICAL THERAPEUTICS, 1987, 10 (01) : 57 - 68
  • [8] Development and validation of an HPLC method for the simultaneous determination of clozapine and desmethylclozapine in plasma of schizophrenic patients
    Raggi, MA
    Bugamelli, F
    Mandrioli, R
    De Ronchi, D
    Volterra, V
    CHROMATOGRAPHIA, 1999, 49 (1-2) : 75 - 80
  • [9] SUPERSENSITIVITY PSYCHOSIS IN SCHIZOPHRENIC-PATIENTS AFTER SUDDEN CLOZAPINE WITHDRAWAL
    EKBLOM, B
    ERIKSSON, K
    LINDSTROM, LH
    PSYCHOPHARMACOLOGY, 1984, 83 (03) : 293 - 294
  • [10] D4 POLYMORPHISMS IN SCHIZOPHRENIC-PATIENTS TREATED WITH CLOZAPINE
    SHAIKH, S
    KERWIN, R
    SHAM, P
    SHARMA, T
    COLLIER, D
    SCHIZOPHRENIA RESEARCH, 1995, 15 (1-2) : 165 - 166
12345